Op2Lysis develops the NANOp2Lysis® platform, which utilizes a novel thrombolytic agent, OptPA, to effectively lyse hematomas and blood clots in hemorrhagic stroke patients. Their lead product, O2L-001, offers a safe and efficient treatment option that reduces disability and mortality associated with acute hemorrhagic strokes.
Funding
Funding not disclosed
Founders
Product
Problem
Hemorrhagic stroke patients face high disability and mortality rates due to the formation of hematomas and blood clots in the brain. Current treatments have limitations in safety and efficacy, creating an unmet need for improved thrombolytic therapies.
Solution
Op2Lysis is developing O2L-001, a therapeutic solution based on their NANOp2Lysis® platform and utilizing OptPA, a novel thrombolytic agent. OptPA is engineered from tissue plasminogen activator (tPA) to improve its safety profile and reduce the risk of bleeding and neurotoxicity. O2L-001 aims to rapidly and safely remove hematomas formed in the brain following a bleeding event, reducing disability and mortality associated with acute hemorrhagic strokes.
Target Audience
The primary target audience includes patients suffering from hemorrhagic stroke and medical professionals seeking improved treatment options for this condition.
Features
- NANOp2Lysis® platform for targeted drug delivery to hematomas and blood clots.
- OptPA: a novel thrombolytic agent optimized for safety and efficacy.
- Reduced pro-bleeding risk compared to existing tPA treatments.
- Specifically optimized to avoid neurotoxicity.
- Easy to use, safe, and effective medicine for hemorrhagic stroke.
- Extended-release technology for reduced dosing frequency.